NEW ORLEANS—A first-in-class peptide-based PET tracer, 18 F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18 ...
The clinical application of PD-L1 immunohistochemistry (IHC) testing is complicated by the availability of multiple IHC assays, scoring algorithms, and cutoffs. This study assessed the analytical ...
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators. PD-L1 expression may assist in predicting ...
This study was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Chinese Thoracic Oncology Group (CTONG)). In this open-label, phase 2 study (NCT04252365), ...
The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...
Hosted on MSN
New immuno-pet tracer superior to FDG PET in predicting PD-L1 expression in head and neck cancer
A first-in-class peptide-based PET tracer, 18 F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18 F-FDG. 18 F-AlF ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback